Clinical advances in hematology & oncology : H&O最新文献

Energy balance in advanced breast cancer: extending beyond the curative setting. 晚期乳腺癌的能量平衡:超出治疗范围。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2022-12-01

Tarah J Ballinger, Martha A Cancilla, Che Young Lee, Jennifer A Ligibel

引用次数: 0

Update on pure red cell aplasia: etiology, diagnosis, and treatment. 纯红细胞发育不全的最新进展:病因、诊断和治疗。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2022-01-01

Robert T Means

引用次数: 0

Changing paradigms in the treatment of acute myeloid leukemia in older patients. 老年急性髓性白血病治疗模式的改变。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2022-01-01

Alexandre Bazinet, Tapan M Kadia

{"title":"Changing paradigms in the treatment of acute myeloid leukemia in older patients.","authors":"Alexandre Bazinet, Tapan M Kadia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals (≥60 years), who constitute the majority of patients with AML, may not always benefit from such intensive approaches owing to increasing frailty, comorbidities, and a higher incidence of adverse-risk disease features. Recent years have seen major advances in the development of effective low-intensity therapies for AML. Low-intensity induction regimens based on hypomethylating agents, venetoclax, and nucleoside analogues are highly effective and safe. A greater emphasis is being placed on the importance of an accurate genetic classification of AML to identify patients who may benefit from novel targeted therapies, such as FLT3 and IDH inhibitors. Genomic classification also highlights a group of patients with high-risk disease (TP53-mutated), for whom improved treatments are urgently needed. Finally, given that relapse is the major cause of treatment failure in elderly patients with AML, innovative maintenance strategies incorporating targeted therapy are being investigated to delay or prevent relapse. In this article, we provide an updated review of the treatment of AML in older patients.</p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"37-46"},"PeriodicalIF":1.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39845608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The next targets for small cell lung cancer. 小细胞肺癌的下一个目标。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2022-01-01

Ravi Salgia

引用次数: 0

Recent data for acalabrutinib in chronic lymphocytic leukemia. 阿卡拉布替尼治疗慢性淋巴细胞白血病的最新数据。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2022-01-01

Paolo Ghia

引用次数: 0

How to choose second-line treatment for hepatocellular carcinoma. 肝细胞癌如何选择二线治疗。